- Sinovac Biotech ( NASDAQ: SVA ) said a phase 3 trial of its quadrivalent influenza vaccine was started in the Republic of Chile in collaboration with Pontificia Universidad Católica de Chile (PI Dr. Pablo González).
- The study will evaluate the vaccine among individuals aged 3 and above and will include up to 1,600 people. Participants will receive either one dose of Sinovac's inactivated vaccine or a different quadrivalent influenza vaccine commercially available in Chile, the company said in a July 19 press release.
- Meanwhile, children aged between three and eight of both groups who have not received any influenza vaccine will receive 2 doses.
- The company noted that all participants will be observed for 28 days following the completed inoculation.
For further details see:
Sinovac begins late-stage trial of influenza vaccine in Chile